Brief: Sam Chun Dang Pharm signs contract worth 3.17 bln won
26/02/2018 03:05
Feb 26 (Reuters) - Sam Chun Dang Pharm Co Ltd 000250.KQ :
* Says it signed a 3.17 billion won contract with Omnivision
GMBH
to provide collyrium incrementally modified drug in Europe
Source text in Korean: https://goo.gl/tuWiZm
Further company coverage: 000250.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Sam Chun Dang Pharm
See all newsBrief: Sam Chun Dang Pharm Co European Medicines Agency Approves Phase I Clinical Study Plan On Oral Insulin In Germany
Brief: Sam Chun Dang Pharm Co To Buy 9.9 Billion Won Worth Of Shares In Optus Pharmaceutical
Brief: Sam Chun Dang Pharm To Divest 29.5 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm To Divest 61 Billion Won Worth Of Own Shares
Brief: Sam Chun Dang Pharm Wins Exclusive Sales Rights To Supply Aflibercept Biosimilar For Treatment Of Macular Degeneration In Germany, Spain, Italy, Switzerland, Austria